Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas

NCT06961565 is registered in ClinicalTrials.gov with Pasithea Therapeutics Corp. as lead sponsor.

NCT NCT06961565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06961565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas
Lead sponsor
Pasithea Therapeutics Corp.
Phase
Phase 1
Overall status
Recruiting
Start date
May 30, 2025
Completion date
December 31, 2027
Enrollment
56 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibroma plexiform, neurofibroma, plexiform, neurofibromatosis type 1 (nf1), neurofibromatosis type 1 (nf1)-related plexiform neurofibromas (pns), nf1 mutation